Dealbreaker on MSN

Presbyopia eye drop from startup Tenpoint gets FDA approval, paving way for $235M financing

Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and ...
Medical Dialogues

FDA Approves First Dual-Agent Eye Drop for Presbyopia

The FDA approved carbachol/brimonidine tartrate ophthalmic solution (Yuvezzi) for adults with presbyopia, marking the first ...
MedPage Today

FDA OKs More Eye Drops That Can Replace Reading Glasses

The FDA approved carbachol/brimonidine tartrate ophthalmic solution (Yuvezzi) for adults with presbyopia, making it the first ...

Tenpoint wins FDA nod for combination presbyopia eye drop

The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...
Ophthalmology Times

FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials

The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...

Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI(TM), the First and Only Combination Eye Drop Approved to Treat Presbyopia

YUVEZZI (TM) (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a ...